期刊簡介 | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Indian Journal of Surgery LetPub Score 5.0
50 ratings
Rate
Reputation 6.4 Influence 3.5 Speed 7.0 | ||||||||||||||||
期刊簡稱 | INDIAN J SURG | ||||||||||||||||
ISSN | 0972-2068 | ||||||||||||||||
E-ISSN | 0973-9793 | ||||||||||||||||
h-index | 17 | ||||||||||||||||
CiteScore |
| ||||||||||||||||
自引率 (2023-2024) | 25.00%自引率趨勢 | ||||||||||||||||
掲載範囲 |
| ||||||||||||||||
官方網站 | https://www.springer.com/12262 | ||||||||||||||||
在線稿件提交 | https://www.editorialmanager.com/ijos/ | ||||||||||||||||
開放訪問 | No | ||||||||||||||||
出版商 | Springer India | ||||||||||||||||
主題領域 | SURGERY | ||||||||||||||||
出版國/地區 | INDIA | ||||||||||||||||
發行頻率 | 隔月刊行 | ||||||||||||||||
創刊年 | 2007 | ||||||||||||||||
每年文章數 | 257每年文章數趨勢 | ||||||||||||||||
黃金OA百分比 | 8.90% | ||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q4
| ||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0972-2068%5BISSN%5D | ||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Slow, 6-12 Week(s) | ||||||||||||||||
競爭力 * | 來自作者的數據: Easy | ||||||||||||||||
參考鏈接 |
| ||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[Indian Journal of Surgery] 的評論 | 撰寫評論 |
作者: Lydia Anne 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-03-16 09:22:21 評論於 Do you need it? I want to make a retrospective(0) 讚! | Lydia Anne |
作者: 白云听春 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-06-12 10:39:23 評論於 Do retrospective studies require clinical trial registration numbers?(0) 讚! | 白云听春 |
作者: Everley Vincent 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-06-03 10:26:50 評論於 Why can't I find the article that has been accepted by Z on PubMed?(0) 讚! | Everley Vincent |
作者: 暴风素洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-03-01 08:47:54 評論於 Review speed: 3.0 | Submission acceptance rate: 75.0 Emphasized research direction: General Surgery Experience sharing: Submitted in September, revised in December, accepted in January of the following year, and published in February. No page fees for copyright. My first SCI paper, very excited and grateful(0) 讚! | 暴风素洁 |
作者: 沃克沃德豪斯 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-02-23 14:32:25 評論於 Have you ever encountered this situation? I received the acceptance letter from him that he needed you to reply to. When I replied, the system actually bounced the email back to me(0) 讚! | 沃克沃德豪斯 |
作者: Everley Vincent 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-01-27 13:06:33 評論於 Do you need to pay for the layout fee?(0) 讚! | Everley Vincent |
作者: 是你的语蓉呀 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-01-25 17:01:53 評論於 Review speed: 3.0 | Submission acceptance rate: 75.0 Experience sharing(0) 讚! | 是你的语蓉呀 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 22:51:17 評論於 It is still necessary for us to clearly explain the limitations of the research in the paper, and to explain how these limitations affect the conclusions of the paper, so that reviewers and other readers can understand that we have fully considered the limitations of the research. Discussing the limitations of the research in the discussion section generally makes the article more credible. Thinking about how to overcome these limitations in future research will have a positive effect(0) 讚! | 维尔娜菲茨杰拉德 |
作者: Everley Vincent 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 18:53:57 評論於 Hello, may I ask how long it took for you to review? I haven't received any feedback after three months of rework(0) 讚! | Everley Vincent |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 10:43:36 評論於 We suggest dividing discussions on research limitations into three parts: (1) identifying research limitations; (2) explaining research limitations in detail; and (3) proposing future research directions or improvement suggestions. Following this order to discuss research limitations can help you clearly point out the research shortcomings without compromising the quality and validity of the study(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 修然小公主 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-26 19:27:41 評論於 Is it necessary to clarify the limitations of the article in the discussion?(0) 讚! | 修然小公主 |
作者: 魂魄彦露 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-26 19:17:41 評論於 How to write about limitations in a discussion?(0) 讚! | 魂魄彦露 |
作者: 火焰端懿 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-15 19:07:44 評論於 Hello everyone, I submitted an article and they are asking for proof from the ethics committee. Is there a template for this? Thank you(0) 讚! | 火焰端懿 |
作者: 暴风素洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-09-27 15:53:10 評論於 The magazine requires peer review for submissions. How should I proceed?(0) 讚! | 暴风素洁 |
作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-07-14 08:50:07 評論於 As long as we can maintain the journals indexed in SCI, it will be fine. If the school adopts CiteScore for evaluation in the future, there is no need to worry. On one hand, CiteScore covers a wider range of journals, so our journal is definitely included. Additionally, it benefits smaller journals, so the difference between them is not so great. I hope the school adopts CiteScore(0) 讚! | 凌霄高洁 |
作者: 璃沙洛妃 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2016-12-26 17:09:00 評論於 Review Speed: 12.0 | Submission Hit Rate: 50.0 Experience Sharing: Submitted in March 2016, underwent major revisions once, minor revisions once, and was accepted at the end of 2016(0) 讚! | 璃沙洛妃 |
作者: Alexander Bacon 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2016-05-02 23:24:24 評論於 It has been one year since the review, and it is still under review. When will it be completed?(0) 讚! | Alexander Bacon |
作者: 桃花傲儿 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2015-04-03 13:17:56 評論於 The review period is too long!!(0) 讚! | 桃花傲儿 |
作者: 玉书姑娘 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2014-11-02 14:34:04 評論於 Review speed: 2.0 | Submission acceptance rate: 75.0 Experience sharing: Indian magazines, relatively good(0) 讚! | 玉书姑娘 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us